Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
R Ossenkoppele, R van der Kant… - The Lancet …, 2022 - thelancet.com
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …
disease and are at very high risk of developing early-onset dementia, which is now the …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
[HTML][HTML] Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs
AR Monteiro, DJ Barbosa, F Remião, R Silva - Biochemical Pharmacology, 2023 - Elsevier
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases that
affect millions of people worldwide, with both prevalence and incidence increasing with age …
affect millions of people worldwide, with both prevalence and incidence increasing with age …
Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease
Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer's disease
S Hu, L Zhang, Y Su, X Liang, J Yang, Q Luo… - Science …, 2024 - science.org
Blood exosomes are emerging as potential biomarkers for diagnosing brain diseases such
as Alzheimer's disease (AD). There is currently a lack of an ultrasensitive technology for …
as Alzheimer's disease (AD). There is currently a lack of an ultrasensitive technology for …
Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study
Background The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in
adults with Down syndrome. Blood biomarkers would be of particular clinical importance in …
adults with Down syndrome. Blood biomarkers would be of particular clinical importance in …
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …